<p>RNS 編號：6387L Polarean Imaging PLC2025 年 12 月 15 日</p>
<p>2025 年 12 月 15 日</p>
<p>Polarean Imaging Plc</p>
<p>（&#34;Polarean&#34;或&#34;公司&#34;）</p>
<p>股東大會結果</p>
<p>關於幫助股東的匹配交易設施的信息</p>
<p>Polarean Imaging plc（AIM：POLX），一家商業階段的醫療技術公司和功能性肺部成像的全球領導者，使用超極化氙 MRI，宣佈在今天早些時候舉行的公司股東大會（&#34;股東大會&#34;）上，所有決議均已通過投票通過。</p>
<p>投票結果的詳細信息如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>決議編號</td>
<td>名稱</td>
<td>支持票數</td>
<td>支持票比例</td>
<td>反對票數</td>
<td>反對票比例</td>
<td>投票棄權 *</td>
</tr>
<tr>
<td>1</td>
<td>取消決議</td>
<td>534,365,742</td>
<td>80.71%</td>
<td>127,743,445</td>
<td>19.29%</td>
<td>2,347,443</td>
</tr>
<tr>
<td>2</td>
<td>重新註冊和採納新章程決議</td>
<td>534,390,927</td>
<td>80.71%</td>
<td>127,740,655</td>
<td>19.29%</td>
<td>2,325,048</td>
</tr>
</tbody>
</table>
<p>* 注：根據英國法律，&#34;投票棄權&#34;不算作投票，並不計入支持或反對決議的計算中。</p>
<p>有效的代理指示已收到，涉及 664,456,630 股普通股，約佔公司已發行股本的 55.05%。</p>
<p>截至 2025 年 12 月 15 日，已發行普通股總數為 1,207,032,781 股。</p>
<p>在股東大會上提出並通過的決議的完整文本可以在公司於 2025 年 11 月 14 日發佈的通函中找到，其中包括股東大會通知（&#34;通函&#34;），並可在公司網站上查閲。公告中使用但未定義的專有名詞應與通函中賦予的含義相同。</p>
<p>AIM 取消</p>
<p>在股東大會上獲得股東批准後，普通股在 AIM 的交易將被取消。取消預計將在 2025 年 12 月 23 日上午 7:00 進行，因此，普通股在 AIM 的最後交易日預計為 2025 年 12 月 22 日。</p>
<p>重新註冊為私人公司</p>
<p>根據決議 2 的通過，公司將重新註冊為私人有限公司，並採納新章程，預計將在 2026 年 1 月 12 日之前完成。</p>
<p>匹配交易設施</p>
<p>公司已安排匹配交易設施，以幫助股東在取消之日起交易普通股。匹配交易設施將由 J P Jenkins 提供，J P Jenkins 是 Prosper Capital LLP 的指定代表，後者已獲得英國金融行為監管局的授權和監管。在匹配交易設施下，股東或希望購買或出售普通股的人可以通過其股票經紀人向 J P Jenkins 留下他們願意購買或出售的普通股數量及其願意的價格。如果 J P Jenkins 能夠將該訂單與相反的賣出或買入指令匹配，它將聯繫雙方並進行交易。取消生效後，匹配交易設施將開始，詳細信息將提供給股東，並可在公司網站（www.polarean.com）上查閲。然而，需要注意的是，無法保證該設施在取消後能為普通股提供流動性。</p>
<p>股東將繼續能夠以無證書形式（即在 CREST 中）持有其股份，並應與其現有的股票經紀人核實他們是否願意或能夠交易未上市股份。</p>
<p>匹配交易設施預計將在取消後至少運行十二個月。目前的意圖是它將繼續超過該時間段，但股東應注意，它可能會在短時間內撤回，從而限制股東交易普通股的能力。董事會將持續審查匹配交易設施的提供，並在決定是否繼續提供匹配交易設施時，公司將考慮預期（和已溝通的）股東對該設施的需求，以及公司成員登記冊的組成和公司及股東的成本。</p>
<p>普通股的指示性定價以及交易歷史將可在 JP Jenkins 網站上查閲，網址為 https://jpjenkins.com/。</p>
<p>諮詢：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Polarean Imaging plc</td>
<td>www.polarean.com / www.polarean-ir.com</td>
</tr>
<tr>
<td>Christopher von Jako, Ph.D., 首席執行官</td>
<td>通過 Walbrook PR</td>
</tr>
<tr>
<td>Charles Osborne, 首席財務官</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Stifel（NOMAD 和唯一的公司經紀人）</td>
<td>電話：+44 (0) 20 7710 7600</td>
</tr>
<tr>
<td>Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Walbrook PR</td>
<td>電話：+44 (0) 20 7933 8780 或 polarean@walbrookpr.com</td>
</tr>
<tr>
<td>Anna Dunphy / Marcus Ulker</td>
<td>手機：+44 (0) 7876741001 / +44 (0) 7867984 082</td>
</tr>
</tbody>
</table>
<p>關於 Polarean</p>
<p>Polarean 是一家產生收入的醫學影像技術公司，通過引入 MRI 的強大和安全性，正在通過直接可視化肺功能來革新肺部醫學。這個社區迫切需要現代解決方案來準確評估肺功能。該公司致力於優化肺健康，防止可避免的損失，通過揭示隱藏的疾病，解決全球超過 5 億名患有慢性呼吸疾病患者的未滿足醫療需求。Polarean 在超極化科學領域處於領先地位，成功開發了首個也是唯一的超極化氙氣 MRI 吸入對比劑 XENOVIEW®，該產品現已獲得美國 FDA 批准。Polarean 致力於研究、開發和商業化創新的影像解決方案，擁有其無創且無輻射的肺功能 MRI 平台。該綜合藥物 - 設備平台包括專有的氙氣混合物、氣體超極化系統，以及軟件和配件，促進現代呼吸影像操作的全面集成。Polarean 成立於 2012 年，辦公室位於北卡羅來納州達勒姆和英國倫敦，致力於提高全球對其 XENOVIEW MRI 技術平台的認識和廣泛訪問。</p>
<p>有關 Polarean 的最新消息和信息，請訪問網站 www.polarean.com</p>
<p>此信息由 RNS 提供，RNS 是倫敦證券交易所的新聞服務。RNS 獲得金融行為監管局的批准，作為英國的主要信息提供者。有關使用和分發此信息的條款和條件可能適用。如需更多信息，請聯繫 rns@lseg.com 或訪問 www.rns.com。</p>
<p>RNS 可能會使用您的 IP 地址以確認遵守條款和條件，分析您與本通信中包含的信息的互動方式，並將此類分析以匿名方式與他人共享，作為我們商業服務的一部分。如需有關 RNS 和倫敦證券交易所如何使用您提供的個人數據的更多信息，請參見我們的隱私政策。END ROMQELFFELLBFBL</p>

<p>Polarean Imaging PLC 宣佈其股東大會上的所有決議均已通過。該公司將於 2025 年 12 月 23 日取消其 AIM 上市，並將在 2026 年 1 月 12 日之前重新註冊為私人有限公司。將提供配對交易設施，以協助股東在取消上市後交易股份。該設施將定期進行審查，並可能在短時間內撤回</p>

<p>RNS Number : 6387L Polarean Imaging PLC 15 December 2025</p>
<div class="lb-trans"><p>RNS 編號：6387L Polarean Imaging PLC2025 年 12 月 15 日</p>
</div><p>15 December 2025</p>
<div class="lb-trans"><p>2025 年 12 月 15 日</p>
</div><p>Polarean Imaging Plc</p>
<div class="lb-trans"><p>Polarean Imaging Plc</p>
</div><p>(&#34;Polarean&#34; or the &#34;Company&#34;)</p>
<div class="lb-trans"><p>（&#34;Polarean&#34;或&#34;公司&#34;）</p>
</div><p>Result of General Meeting</p>
<div class="lb-trans"><p>股東大會結果</p>
</div><p>Information on Matched Bargain Facility to assist shareholders</p>
<div class="lb-trans"><p>關於幫助股東的匹配交易設施的信息</p>
</div><p>Polarean Imaging plc (AIM: POLX), a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI, announces that at the general meeting of the Company (&#34;General Meeting&#34;) held earlier today, all resolutions were duly passed on a poll.</p>
<div class="lb-trans"><p>Polarean Imaging plc（AIM：POLX），一家商業階段的醫療技術公司和功能性肺部成像的全球領導者，使用超極化氙 MRI，宣佈在今天早些時候舉行的公司股東大會（&#34;股東大會&#34;）上，所有決議均已通過投票通過。</p>
</div><p>Details of the poll results are set out below:</p>
<div class="lb-trans"><p>投票結果的詳細信息如下：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolution Number</td>
<td>Name</td>
<td>Votes for</td>
<td>% of votes for</td>
<td>Votes against</td>
<td>% of votes against</td>
<td>Votes withheld*</td>
</tr>
<tr>
<td>1</td>
<td>Cancellation Resolution</td>
<td>534,365,742</td>
<td>80.71%</td>
<td>127,743,445</td>
<td>19.29%</td>
<td>2,347,443</td>
</tr>
<tr>
<td>2</td>
<td>Re-registration and adoption of new articles of association Resolution</td>
<td>534,390,927</td>
<td>80.71%</td>
<td>127,740,655</td>
<td>19.29%</td>
<td>2,325,048</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>決議編號</td>
<td>名稱</td>
<td>支持票數</td>
<td>支持票比例</td>
<td>反對票數</td>
<td>反對票比例</td>
<td>投票棄權 *</td>
</tr>
<tr>
<td>1</td>
<td>取消決議</td>
<td>534,365,742</td>
<td>80.71%</td>
<td>127,743,445</td>
<td>19.29%</td>
<td>2,347,443</td>
</tr>
<tr>
<td>2</td>
<td>重新註冊和採納新章程決議</td>
<td>534,390,927</td>
<td>80.71%</td>
<td>127,740,655</td>
<td>19.29%</td>
<td>2,325,048</td>
</tr>
</tbody>
</table>
</div><p>*Note: A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.</p>
<div class="lb-trans"><p>* 注：根據英國法律，&#34;投票棄權&#34;不算作投票，並不計入支持或反對決議的計算中。</p>
</div><p>Valid proxy instructions were received in respect of 664,456,630 Ordinary Shares representing approximately 55.05% of the issued share capital of the Company.</p>
<div class="lb-trans"><p>有效的代理指示已收到，涉及 664,456,630 股普通股，約佔公司已發行股本的 55.05%。</p>
</div><p>The total number of Ordinary Shares in issue as at 15 December 2025 is 1,207,032,781.</p>
<div class="lb-trans"><p>截至 2025 年 12 月 15 日，已發行普通股總數為 1,207,032,781 股。</p>
</div><p>The full text of the Resolutions proposed and passed at the General Meeting can be found in the circular of the Company containing, inter alia, the notice of General Meeting, which was published on 14 November 2025 (the &#34;Circular&#34;) and is available on the Company's website here. Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.</p>
<div class="lb-trans"><p>在股東大會上提出並通過的決議的完整文本可以在公司於 2025 年 11 月 14 日發佈的通函中找到，其中包括股東大會通知（&#34;通函&#34;），並可在公司網站上查閲。公告中使用但未定義的專有名詞應與通函中賦予的含義相同。</p>
</div><p>AIM Cancellation</p>
<div class="lb-trans"><p>AIM 取消</p>
</div><p>Following approval by Shareholders at the General Meeting, the admission of the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is expected to take place at 7:00 a.m. on 23 December 2025 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 22 December 2025.</p>
<div class="lb-trans"><p>在股東大會上獲得股東批准後，普通股在 AIM 的交易將被取消。取消預計將在 2025 年 12 月 23 日上午 7:00 進行，因此，普通股在 AIM 的最後交易日預計為 2025 年 12 月 22 日。</p>
</div><p>Re-registration as a private company</p>
<div class="lb-trans"><p>重新註冊為私人公司</p>
</div><p>In accordance with the passing of Resolution 2, the Company will re-register as a private limited company and adopt new articles of association, which is expected to take place by 12 January 2026.</p>
<div class="lb-trans"><p>根據決議 2 的通過，公司將重新註冊為私人有限公司，並採納新章程，預計將在 2026 年 1 月 12 日之前完成。</p>
</div><p>Matched Bargain Facility</p>
<div class="lb-trans"><p>匹配交易設施</p>
</div><p>The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation.</p>
<div class="lb-trans"><p>公司已安排匹配交易設施，以幫助股東在取消之日起交易普通股。匹配交易設施將由 J P Jenkins 提供，J P Jenkins 是 Prosper Capital LLP 的指定代表，後者已獲得英國金融行為監管局的授權和監管。在匹配交易設施下，股東或希望購買或出售普通股的人可以通過其股票經紀人向 J P Jenkins 留下他們願意購買或出售的普通股數量及其願意的價格。如果 J P Jenkins 能夠將該訂單與相反的賣出或買入指令匹配，它將聯繫雙方並進行交易。取消生效後，匹配交易設施將開始，詳細信息將提供給股東，並可在公司網站（www.polarean.com）上查閲。然而，需要注意的是，無法保證該設施在取消後能為普通股提供流動性。</p>
</div><p>Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares.</p>
<div class="lb-trans"><p>股東將繼續能夠以無證書形式（即在 CREST 中）持有其股份，並應與其現有的股票經紀人核實他們是否願意或能夠交易未上市股份。</p>
</div><p>The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders.</p>
<div class="lb-trans"><p>匹配交易設施預計將在取消後至少運行十二個月。目前的意圖是它將繼續超過該時間段，但股東應注意，它可能會在短時間內撤回，從而限制股東交易普通股的能力。董事會將持續審查匹配交易設施的提供，並在決定是否繼續提供匹配交易設施時，公司將考慮預期（和已溝通的）股東對該設施的需求，以及公司成員登記冊的組成和公司及股東的成本。</p>
</div><p>The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.</p>
<div class="lb-trans"><p>普通股的指示性定價以及交易歷史將可在 JP Jenkins 網站上查閲，網址為 https://jpjenkins.com/。</p>
</div><p>Enquiries:</p>
<div class="lb-trans"><p>諮詢：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Polarean Imaging plc</td>
<td>www.polarean.com / www.polarean-ir.com</td>
</tr>
<tr>
<td>Christopher von Jako, Ph.D., Chief Executive Officer</td>
<td>Via Walbrook PR</td>
</tr>
<tr>
<td>Charles Osborne, Chief Financial Officer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Stifel (NOMAD and Sole Corporate Broker)</td>
<td>Tel: +44 (0) 20 7710 7600</td>
</tr>
<tr>
<td>Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Walbrook PR</td>
<td>Tel: +44 (0) 20 7933 8780 or polarean@walbrookpr.com</td>
</tr>
<tr>
<td>Anna Dunphy / Marcus Ulker</td>
<td>Mob: +44 (0) 7876741001 / +44 (0) 7867984 082</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Polarean Imaging plc</td>
<td>www.polarean.com / www.polarean-ir.com</td>
</tr>
<tr>
<td>Christopher von Jako, Ph.D., 首席執行官</td>
<td>通過 Walbrook PR</td>
</tr>
<tr>
<td>Charles Osborne, 首席財務官</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Stifel（NOMAD 和唯一的公司經紀人）</td>
<td>電話：+44 (0) 20 7710 7600</td>
</tr>
<tr>
<td>Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Walbrook PR</td>
<td>電話：+44 (0) 20 7933 8780 或 polarean@walbrookpr.com</td>
</tr>
<tr>
<td>Anna Dunphy / Marcus Ulker</td>
<td>手機：+44 (0) 7876741001 / +44 (0) 7867984 082</td>
</tr>
</tbody>
</table>
</div><p>About Polarean</p>
<div class="lb-trans"><p>關於 Polarean</p>
</div><p>Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.</p>
<div class="lb-trans"><p>Polarean 是一家產生收入的醫學影像技術公司，通過引入 MRI 的強大和安全性，正在通過直接可視化肺功能來革新肺部醫學。這個社區迫切需要現代解決方案來準確評估肺功能。該公司致力於優化肺健康，防止可避免的損失，通過揭示隱藏的疾病，解決全球超過 5 億名患有慢性呼吸疾病患者的未滿足醫療需求。Polarean 在超極化科學領域處於領先地位，成功開發了首個也是唯一的超極化氙氣 MRI 吸入對比劑 XENOVIEW®，該產品現已獲得美國 FDA 批准。Polarean 致力於研究、開發和商業化創新的影像解決方案，擁有其無創且無輻射的肺功能 MRI 平台。該綜合藥物 - 設備平台包括專有的氙氣混合物、氣體超極化系統，以及軟件和配件，促進現代呼吸影像操作的全面集成。Polarean 成立於 2012 年，辦公室位於北卡羅來納州達勒姆和英國倫敦，致力於提高全球對其 XENOVIEW MRI 技術平台的認識和廣泛訪問。</p>
</div><p>For the latest news and information about Polarean, please visit the website at www.polarean.com</p>
<div class="lb-trans"><p>有關 Polarean 的最新消息和信息，請訪問網站 www.polarean.com</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是倫敦證券交易所的新聞服務。RNS 獲得金融行為監管局的批准，作為英國的主要信息提供者。有關使用和分發此信息的條款和條件可能適用。如需更多信息，請聯繫 rns@lseg.com 或訪問 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ROMQELFFELLBFBL</p>
<div class="lb-trans"><p>RNS 可能會使用您的 IP 地址以確認遵守條款和條件，分析您與本通信中包含的信息的互動方式，並將此類分析以匿名方式與他人共享，作為我們商業服務的一部分。如需有關 RNS 和倫敦證券交易所如何使用您提供的個人數據的更多信息，請參見我們的隱私政策。END ROMQELFFELLBFBL</p>
</div>

REG - Polarean Imaging PLC - 股東大會結果